(CBT) Cabot - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1270551013

CBT EPS (Earnings per Share)

This chart shows the EPS (Earnings per Share) of CBT over the last 5 years for every Quarter.

CBT Revenue

This chart shows the Revenue of CBT over the last 5 years for every Quarter.

CBT: Carbon, Additives, Conductive, Silica, Aerogel

Cabot Corporation is a leading global specialty chemicals and performance materials company, operating through two main segments: Reinforcement Materials and Performance Chemicals. The companys products play a crucial role in various industries, including automotive, industrial, electronics, and consumer goods. Its reinforcing carbons and engineered elastomer composites solutions are used in tire manufacturing and industrial products, while its specialty carbons and conductive additives are used in inks, coatings, plastics, and batteries. Additionally, Cabots fumed silica and alumina are used in a range of applications, from adhesives and cosmetics to batteries and pharmaceuticals.

The companys diverse product portfolio also includes aerogel, a high-performance insulation material, and masterbatch and conductive compound products used in various industries. Cabots products are sold through a global network of distributors and sales representatives, with a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. With a rich history dating back to 1882, Cabot Corporation is headquartered in Boston, Massachusetts, and is committed to delivering innovative solutions to its customers.

From a technical analysis perspective, Cabots stock price has been trending downwards, with the current price of $75.06 below its 50-day SMA of $76.84 and 200-day SMA of $92.47. The ATR of 1.98 indicates a relatively low volatility, but the stock is currently trading near its 52-week low of $72.04. Considering the fundamental data, Cabots market capitalization stands at $4012.58M USD, with a P/E ratio of 9.69 and a forward P/E of 10.32, indicating a relatively undervalued stock. The companys RoE of 31.13% suggests a strong profitability.

Based on the technical and fundamental data, a forecast for Cabot Corporations stock price could be made. With the current price near its 52-week low and a relatively low P/E ratio, the stock may be due for a rebound. If the companys RoE continues to be strong, it could drive the stock price upwards. However, the downward trend in the stock price and the high 200-day SMA may indicate a longer-term bearish trend. A potential trading strategy could be to buy the stock at the current price, with a stop-loss at around $72.04, and a target price of $80-$85, based on the stocks historical volatility and fundamental data.

Additional Sources for CBT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

CBT Stock Overview

Market Cap in USD 4,014m
Sector Basic Materials
Industry Specialty Chemicals
GiC Sub-Industry Commodity Chemicals
IPO / Inception 1980-11-05

CBT Stock Ratings

Growth Rating 50.0
Fundamental 53.0
Dividend Rating 60.2
Rel. Strength -19.9
Analysts 3.6 of 5
Fair Price Momentum 71.46 USD
Fair Price DCF 105.38 USD

CBT Dividends

Dividend Yield 12m 2.11%
Yield on Cost 5y 5.35%
Annual Growth 5y 3.84%
Payout Consistency 89.5%
Payout Ratio 23.6%

CBT Growth Ratios

Growth Correlation 3m -72.4%
Growth Correlation 12m -75.4%
Growth Correlation 5y 92.4%
CAGR 5y 18.06%
CAGR/Max DD 5y 0.48
Sharpe Ratio 12m -1.78
Alpha -31.18
Beta 0.887
Volatility 33.75%
Current Volume 260.4k
Average Volume 20d 330.5k
What is the price of CBT shares?
As of June 24, 2025, the stock is trading at USD 74.57 with a total of 260,416 shares traded.
Over the past week, the price has changed by +0.15%, over one month by +1.39%, over three months by -10.77% and over the past year by -20.96%.
Is Cabot a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, Cabot (NYSE:CBT) is currently (June 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 53.03 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CBT is around 71.46 USD . This means that CBT is currently overvalued and has a potential downside of -4.17%.
Is CBT a buy, sell or hold?
Cabot has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold CBT.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0
What are the forecasts for CBT share price target?
According to our own proprietary Forecast Model, CBT Cabot will be worth about 78.8 in June 2026. The stock is currently trading at 74.57. This means that the stock has a potential upside of +5.69%.
Issuer Target Up/Down from current
Wallstreet Target Price 83.6 12.1%
Analysts Target Price 83.6 12.1%
ValueRay Target Price 78.8 5.7%